Patent · US Active

Antisense compounds targeting genes associated with cystic fibrosis

US11116785B2 · kind B2 · utility

1Cited by
6References
33Claims
0Family size

Assignee

Inventor

Key dates

Filing dateDec 30, 2019
Grant dateSep 14, 2021
Priority date—
Expiry dateDec 30, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12N2320/33
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates generally to compounds comprising oligonucleotides complementary to a cystic fibrosis transmembrane conductance regulator (CFTR) RNA transcript. Certain such compounds are useful for hybridizing to a CFTR RNA transcript, including but not limited to a CFTR RNA transcript in a cell. In certain embodiments, such hybridization results in modulation of splicing of the CFTR transcript. In certain embodiments, such compounds are used to treat one or more symptoms associated with Cystic Fibrosis.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.